Sun Hong-xin, Qin Jin, Zhou Yi-qiang
Henan Provincial Traditional Chinese Medicine Hospital, Zhengzhou.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 Jan;29(1):23-5.
To objectively assess the influence of Xiaoliu Baofei Pill (XBP) combined with chemotherapy on quality of life (QOL) of patients with stage III-IV non-small cell lung cancer (NSCLC).
Forty NSCLC patients were equally randomized into 2 groups, the treated group treated with XBP plus chemotherapy, and the control group treated with chemotherapy alone. Patients' QOL was assessed by Functional Assessment of Cancer Therapy (FACT-L) before and after treatment.
The scores of the physical condition in the treated group was relatively stable while it lowered significantly as time went by in the control group, significant difference was shown as compared with before treatment and with that in the treated group at the same time points (P < 0.05); scores of the mood condition, the function conditions and additional concerned condition were improved gradually from the 3rd collection in the treated group, but decreased in the control group, although some improvement of mood and function conditions had revealed temporarily in the early stage of treatment. Comparison between groups showed significant difference (P < 0.05). Besides, no significant change was found in domains of patient-doctor relation and society/family condition in both groups.
XBP combined with chemotherapy can obviously improve the QOL of advanced NSCLC patients.
客观评估消瘤保肺丸（XBP）联合化疗对Ⅲ-Ⅳ期非小细胞肺癌（NSCLC）患者生活质量（QOL）的影响。
40例NSCLC患者被随机均分为2组，治疗组采用XBP加化疗治疗，对照组单纯化疗。治疗前后采用癌症治疗功能评价量表（FACT-L）评估患者的QOL。
治疗组身体状况评分相对稳定，而对照组随时间推移显著降低，与治疗前及治疗组同期相比差异有统计学意义（P<0.05）；治疗组情绪状况、功能状况及附加关注状况评分从第3次收集时开始逐渐改善，而对照组降低，尽管治疗早期情绪和功能状况有暂时改善。组间比较差异有统计学意义（P<0.05）。此外，两组患者的医患关系及社会/家庭状况方面无明显变化。
XBP联合化疗可明显改善晚期NSCLC患者的QOL。
